Late brake abstract på ESMO neste uke. Blir kunngjort i morgen.
Er bare en teoretisk mulighet for det, men still.
1 Like
Han mener nok dette;
»Abstracts accepted for presentation at the ESMO Immuno-Oncology Congress 2019 as Proffered Paper (oral presentation), Mini Oral and Poster will be published online on the ESMO website at 12:00 CET on Thursday, 5 December 2019.»
2 Likes
Ser ud til vi åbner op igen i dag … så må vi se, om den fortsat kan lukke i plus.
Level 2 fornægter sig ikke …
2 Likes
Det blir litt rimeligere julegaver fra denne kanten i år ja.
Kan rett og slett ikke vente lengre med å øke posten her.
Blir nok finere julegaver neste år kan jeg love 
ESMO Abstract lagt ut i dag om TG01 (vet ikke om det er så mye nytt):
24P - Multiple KRAS mutations detected by cancer related DNA in patients with resected pancreas adenocarcinoma during treatment with TG01/GM-CSF and gemcitabine (CT TG01-01)
Presentation Number 24P
Lecture Time 12:15 - 12:15
Speakers
- D. Palmer (liverpool, United Kingdom)
Authors
-
D. Palmer (liverpool, United Kingdom)
-
A. Møller (Oslo, Norway)
-
B. Greenhalf (Liverpool, United Kingdom)
-
Y. Ma (Birmingham, United Kingdom)
-
J. Valle (Manchester, United Kingdom)
-
T. Gjertsen (Oslo, Norway)
-
L. Kuryk (Oslo, Finland)
Background
TG01/GM-CSF is an injectable antigen-specific cancer immunotherapy targeted to treat patients (pts) with KRAS mutations, found in > 90% of pancreatic adenocarcinomas (PAC). TG01 consists of a mixture of 7 synthetic peptides representing 7 of the most common codon 12 and 13 mutations associated with PAC. Pancreatic cancer is a heterogeneous and genetically unstable disease, meaning that more than one KRAS mutation may be present in a single tumor. We investigated if cancer-related DNA from pts with resected PAC had more than one KRAS mutation and if the mutation status changed during treatment with TG01/GM-CSF.
Methods
Pts were eligible after an R0 or R1 PAC resection. TG01 (0.7 mg intradermal injection id) together with GM-CSF (0.03 mg id) was given on day 1, 3, 5, 8, 15, 22 and 2-weekly until end of chemotherapy, 4-weekly up to 1 year and 12-weekly up to 2 yrs. Within 12 weeks after resection, pts were expected to receive gemcitabine for 6 cycles. Plasma samples (up to 9) from 21 pts were collected and cancer related KRAS DNA were analyzed using ARMS (real time qPCR) for the 6 most common mutations: 12D, 12V, 12A, 12R, 12S and 12C.
Results
21 pts from UK, median age 65 (46-77) enrolled between Jan-2014 and Apr-2016. Previous results from tumor specimen showed that 16 out of 21 pts had a KRAS mutation (single mutation). However, when analyzing mutations using ARMS 20 out of 21 pts had ≥1 KRAS mutations; 19 out of 21 pts (90%) had between 1-6 mutations throughout the study. 12D and 12V mutations co-occurred in 17 out of 21 (81%) of the pts. In one pt all 6 assessed KRAS mutations were detected throughout the study. In 5 pts mutations disappeared during the treatment while in 10 pts the mutations changed either revealing new mutations or shift of mutations over time, possibly indicating selection pressure.
Conclusion
The great majority of patients with PAC have multiple KRAS mutations; in addition, mutations changed during the course of the study. Single mutation vaccines and small molecules targeting single mutations are therefore unlikely to be effective while therapies targeting a mix of KRAS mutations (TG01) may be more beneficial.
Clinical trial identification
CT TG01-01; EudraCT: 2012-002400-40.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
9 Likes
4 Likes
Greier de å unngå å legge ned TG en tredje gang, så må jo dette gå veien! 
5 Likes
hva tenker vi ? 
3 Likes
Du liker TG du;)
Selv har jeg bare lagt den muligheten dø, men ble litt overrasket når dette abstraktet poppet opp:)
2 Likes
Jeg elsker gode nyheter på en positiv biotek-børs!
1 Like
Ser man på selskabets portefølje er der jo en bred vifte af patenter omkring RAS; med andre ord, stærke kort at have på hånden i et marked der i stigende grad bliver bevidst omkring variationer over temaet onkologi.
og …
og mange flere …
2 Likes
6,00 er en realitet på svært stærk volumen; følg med nu. Ikke lang til at tangere tirsdagens volumen …
6 Likes
6 Likes
Jeg ligger inne med 500 MNOK for TG, jeg tror effektene er for gode til at de skal bli oversett og glemt.
3 Likes
Jeg er også en av de skyldige 
Deilig å se volumet øker i takt med kursen!!!
3 Likes
Var nok ikke meg;)
Sitter bare med longporteføljen igjen i Pho, den selges ikke.
Men utrolig gøy at markedet begynne å få opp øyene for Targovax!
2 Likes
Tenk om vi får en børsmelding før helga hvor de korrigerer 1cr og 2 pr til 3 cr. Da må man unne seg noe jordbær-tærte!
2 Likes